BIOGEN INC. Other than Temporary Impairment Losses, Investments
BIOGEN INC. (BIIB) reported Other than Temporary Impairment Losses, Investments of $0 for the 12-month period ending 2015-12-31, per its 10-K filed 2016-02-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfInvestments · last filed 2016-02-03
- BIOGEN INC. other than temporary impairment losses, investments for the quarter ending 2014-12-31 was $0.00, a 100.00% decline year-over-year.
- BIOGEN INC. other than temporary impairment losses, investments for the quarter ending 2014-09-30 was $0.00.
- BIOGEN INC. other than temporary impairment losses, investments for the quarter ending 2014-06-30 was $0.00, a 100.00% decline year-over-year.
- BIOGEN INC. other than temporary impairment losses, investments for the quarter ending 2014-03-31 was $0.00, a 100.00% decline year-over-year.
- BIOGEN INC. other than temporary impairment losses, investments for fiscal 2015 was $0.00.
- BIOGEN INC. other than temporary impairment losses, investments for fiscal 2014 was $0.00, a 100.00% decline from fiscal 2013.
- BIOGEN INC. other than temporary impairment losses, investments for fiscal 2013 was $2.80M, a 49.09% decline from fiscal 2012.
- BIOGEN INC. other than temporary impairment losses, investments for fiscal 2012 was $5.50M, a 44.44% decline from fiscal 2011.
| Period end | Other than Temporary Impairment Losses, Investments 3 month | Other than Temporary Impairment Losses, Investments 3 month as first filed | Other than Temporary Impairment Losses, Investments 6 month | Other than Temporary Impairment Losses, Investments 6 month as first filed | Other than Temporary Impairment Losses, Investments 9 month | Other than Temporary Impairment Losses, Investments 9 month as first filed | Other than Temporary Impairment Losses, Investments 12 month | Other than Temporary Impairment Losses, Investments 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2015-12-31 | $0.00 10-K · filed 2016-02-03 | |||||||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-03 | $0.00 derived: sum of 2 quarters · filed 2016-02-03 | $0.00 derived: sum of 3 quarters · filed 2016-02-03 | $0.00 10-K · filed 2016-02-03 | ||||
| 2014-09-30 | $0.00 10-Q · filed 2014-10-22 | $0.00 derived: sum of 2 quarters · filed 2014-10-22 | $0.00 10-Q · filed 2014-10-22 | $1.10M derived: sum of 4 quarters · filed 2016-02-03 | ||||
| 2014-06-30 | $0.00 10-Q · filed 2014-07-23 | $0.00 10-Q · filed 2014-07-23 | $1.10M derived: sum of 3 quarters · filed 2016-02-03 | $1.10M derived: sum of 4 quarters · filed 2016-02-03 | ||||
| 2014-03-31 | $0.00 10-Q · filed 2014-04-23 | $1.10M derived: sum of 2 quarters · filed 2016-02-03 | $1.10M derived: sum of 3 quarters · filed 2016-02-03 | $2.50M derived: sum of 4 quarters · filed 2016-02-03 | ||||
| 2013-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-03 | $1.10M derived: sum of 2 quarters · filed 2016-02-03 | $2.50M derived: sum of 3 quarters · filed 2016-02-03 | $2.80M 10-K · filed 2016-02-03 | ||||
| 2013-09-30 | $0.00 10-Q · filed 2014-10-22 | $1.40M derived: sum of 2 quarters · filed 2014-10-22 | $1.70M 10-Q · filed 2014-10-22 | $2.40M derived: sum of 4 quarters · filed 2015-02-04 | ||||
| 2013-06-30 | $1.40M 10-Q · filed 2014-07-23 | $1.70M 10-Q · filed 2014-07-23 | $2.40M derived: sum of 3 quarters · filed 2015-02-04 | $5.90M derived: sum of 4 quarters · filed 2015-02-04 | ||||
| 2013-03-31 | $300.00K 10-Q · filed 2014-04-23 | $1.00M derived: sum of 2 quarters · filed 2015-02-04 | $4.50M derived: sum of 3 quarters · filed 2015-02-04 | $5.30M derived: sum of 4 quarters · filed 2015-02-04 | ||||
| 2012-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-04 | $4.20M derived: sum of 2 quarters · filed 2015-02-04 | $5.00M derived: sum of 3 quarters · filed 2015-02-04 | $5.50M 10-K · filed 2015-02-04 | ||||
| 2012-09-30 | $3.50M 10-Q · filed 2013-10-28 | $4.30M derived: sum of 2 quarters · filed 2013-10-28 | $4.80M 10-Q · filed 2013-10-28 | $7.10M derived: sum of 4 quarters · filed 2014-02-06 | ||||
| 2012-06-30 | $800.00K 10-Q · filed 2013-07-25 | $1.30M 10-Q · filed 2013-07-25 | $3.60M derived: sum of 3 quarters · filed 2014-02-06 | $4.40M derived: sum of 4 quarters · filed 2014-02-06 | ||||
| 2012-03-31 | $500.00K 10-Q · filed 2013-04-25 | $2.80M derived: sum of 2 quarters · filed 2014-02-06 | $3.60M derived: sum of 3 quarters · filed 2014-02-06 | $8.80M derived: sum of 4 quarters · filed 2014-02-06 | ||||
| 2011-12-31 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-06 | $3.10M derived: sum of 2 quarters · filed 2014-02-06 | $8.30M derived: sum of 3 quarters · filed 2014-02-06 | $9.90M 10-K · filed 2014-02-06 | $11.50M 10-K · filed 2012-02-03 | |||
| 2011-09-30 | $800.00K 10-Q · filed 2012-10-25 | $6.00M derived: sum of 2 quarters · filed 2012-10-25 | $7.60M 10-Q · filed 2012-10-25 | $5.70M derived: sum of 4 quarters · filed 2013-02-05 | ||||
| 2011-06-30 | $5.20M 10-Q · filed 2012-07-24 | $5.50M 10-Q · filed 2011-07-26 | $5.50M 10-Q · filed 2012-07-24 | $6.80M 10-Q · filed 2011-07-26 | $4.90M derived: sum of 3 quarters · filed 2013-02-05 | $7.70M derived: sum of 4 quarters · filed 2013-02-05 | ||
| 2011-03-31 | $300.00K 10-Q · filed 2012-05-01 | $1.20M 10-Q · filed 2011-04-21 | -$300.00K derived: sum of 2 quarters · filed 2013-02-05 | $2.50M derived: sum of 3 quarters · filed 2013-02-05 | $3.70M derived: sum of 4 quarters · filed 2013-02-05 | |||
| 2010-12-31 | -$600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $2.20M derived: sum of 2 quarters · filed 2013-02-05 | $3.40M derived: sum of 3 quarters · filed 2013-02-05 | $19.20M 10-K · filed 2013-02-05 | $21.30M 10-K · filed 2011-02-04 | |||
| 2010-09-30 | $2.80M 10-Q · filed 2011-10-28 | $4.00M derived: sum of 2 quarters · filed 2011-10-28 | $19.80M 10-Q · filed 2011-10-28 | $20.30M derived: sum of 4 quarters · filed 2012-02-03 | ||||
| 2010-06-30 | $1.20M 10-Q · filed 2011-07-26 | $17.00M 10-Q · filed 2011-07-26 | $17.50M derived: sum of 3 quarters · filed 2012-02-03 | $18.00M derived: sum of 4 quarters · filed 2012-02-03 | ||||
| 2010-03-31 | $15.80M 10-Q · filed 2011-04-21 | $16.11M 10-Q · filed 2010-04-20 | $16.30M derived: sum of 2 quarters · filed 2012-02-03 | $16.80M derived: sum of 3 quarters · filed 2012-02-03 | $20.30M derived: sum of 4 quarters · filed 2012-02-03 | |||
| 2009-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03 | $1.00M derived: sum of 2 quarters · filed 2012-02-03 | $4.50M derived: sum of 3 quarters · filed 2012-02-03 | $10.60M 10-K · filed 2012-02-03 | $16.18M 10-K · filed 2010-02-09 | |||
| 2009-09-30 | $500.00K 10-Q · filed 2010-10-26 | $4.00M derived: sum of 2 quarters · filed 2010-10-26 | $10.10M 10-Q · filed 2010-10-26 | $9.87M 10-Q · filed 2009-10-21 | $38.82M derived: sum of 4 quarters · filed 2011-02-04 | |||
| 2009-06-30 | $3.50M 10-Q · filed 2010-07-20 | $9.60M 10-Q · filed 2010-07-20 | $10.00M 10-Q · filed 2009-07-17 | $38.32M derived: sum of 3 quarters · filed 2011-02-04 | $54.37M derived: sum of 4 quarters · filed 2011-02-04 | |||
| 2009-03-31 | $6.02M 10-Q · filed 2010-04-20 | $34.82M derived: sum of 2 quarters · filed 2011-02-04 | $50.87M derived: sum of 3 quarters · filed 2011-02-04 | |||||
| 2008-12-31 | $28.80M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-04 | $44.85M derived: sum of 2 quarters · filed 2011-02-04 | $60.30M 10-K · filed 2011-02-04 | $61.64M 10-K · filed 2010-02-09 | ||||
| 2008-09-30 | $16.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2009-10-21 | $31.50M 10-Q · filed 2009-10-21 | ||||||
| 2008-06-30 | $15.45M 10-Q · filed 2009-07-17 | |||||||
| 2007-12-31 | $24.45M 10-K · filed 2010-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |